Industry Updates

Amgen’s Personalized Strategy for Cancer Pays Off in Big Colon Cancer Trial | Xconomy11 Aug

An exciting success story for personalized medicine – Amgen demonstrates that its colon cancer treatment Vectibix works markedly better for patients without a mutated KRAS gene. Whether this drug is worth $8000 a month for you or not can be predicted by a single SNP biomarker.

http://www.xconomy.com/national/2009/08/10/amgens-personalized-strategy-for-cancer-pays-off-in-big-colon-cancer-trial/

Leave a Reply

Company News

  • - 2013/03/04

    One of our team members is now working with Hospira on infuser product support. Contact us to find out more!

  • - 2010/10/24

    We're currently working with online elections provider Everyone Counts, Inc. Contact us to find out more!

Contact Us